Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model

Abstract Background Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and testosterone have been positively asso...

Full description

Bibliographic Details
Main Authors: Tess V. Clendenen, Wenzhen Ge, Karen L. Koenig, Yelena Afanasyeva, Claudia Agnoli, Louise A. Brinton, Farbod Darvishian, Joanne F. Dorgan, A. Heather Eliassen, Roni T. Falk, Göran Hallmans, Susan E. Hankinson, Judith Hoffman-Bolton, Timothy J. Key, Vittorio Krogh, Hazel B. Nichols, Dale P. Sandler, Minouk J. Schoemaker, Patrick M. Sluss, Malin Sund, Anthony J. Swerdlow, Kala Visvanathan, Anne Zeleniuch-Jacquotte, Mengling Liu
Format: Article
Language:English
Published: BMC 2019-03-01
Series:Breast Cancer Research
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13058-019-1126-z
id doaj-5173ace532a544d39c8c04eefe3f07c5
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Tess V. Clendenen
Wenzhen Ge
Karen L. Koenig
Yelena Afanasyeva
Claudia Agnoli
Louise A. Brinton
Farbod Darvishian
Joanne F. Dorgan
A. Heather Eliassen
Roni T. Falk
Göran Hallmans
Susan E. Hankinson
Judith Hoffman-Bolton
Timothy J. Key
Vittorio Krogh
Hazel B. Nichols
Dale P. Sandler
Minouk J. Schoemaker
Patrick M. Sluss
Malin Sund
Anthony J. Swerdlow
Kala Visvanathan
Anne Zeleniuch-Jacquotte
Mengling Liu
spellingShingle Tess V. Clendenen
Wenzhen Ge
Karen L. Koenig
Yelena Afanasyeva
Claudia Agnoli
Louise A. Brinton
Farbod Darvishian
Joanne F. Dorgan
A. Heather Eliassen
Roni T. Falk
Göran Hallmans
Susan E. Hankinson
Judith Hoffman-Bolton
Timothy J. Key
Vittorio Krogh
Hazel B. Nichols
Dale P. Sandler
Minouk J. Schoemaker
Patrick M. Sluss
Malin Sund
Anthony J. Swerdlow
Kala Visvanathan
Anne Zeleniuch-Jacquotte
Mengling Liu
Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
Breast Cancer Research
Breast cancer risk prediction
Anti-Müllerian hormone
Testosterone
Gail model
author_facet Tess V. Clendenen
Wenzhen Ge
Karen L. Koenig
Yelena Afanasyeva
Claudia Agnoli
Louise A. Brinton
Farbod Darvishian
Joanne F. Dorgan
A. Heather Eliassen
Roni T. Falk
Göran Hallmans
Susan E. Hankinson
Judith Hoffman-Bolton
Timothy J. Key
Vittorio Krogh
Hazel B. Nichols
Dale P. Sandler
Minouk J. Schoemaker
Patrick M. Sluss
Malin Sund
Anthony J. Swerdlow
Kala Visvanathan
Anne Zeleniuch-Jacquotte
Mengling Liu
author_sort Tess V. Clendenen
title Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
title_short Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
title_full Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
title_fullStr Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
title_full_unstemmed Breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail model
title_sort breast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the gail model
publisher BMC
series Breast Cancer Research
issn 1465-542X
publishDate 2019-03-01
description Abstract Background Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and testosterone have been positively associated with breast cancer risk in prospective studies. We assessed whether adding AMH and/or testosterone to the Gail model improves its prediction performance for women aged 35–50. Methods In a nested case-control study including ten prospective cohorts (1762 invasive cases/1890 matched controls) with pre-diagnostic serum/plasma samples, we estimated relative risks (RR) for the biomarkers and Gail risk factors using conditional logistic regression and random-effects meta-analysis. Absolute risk models were developed using these RR estimates, attributable risk fractions calculated using the distributions of the risk factors in the cases from the consortium, and population-based incidence and mortality rates. The area under the receiver operating characteristic curve (AUC) was used to compare the discriminatory accuracy of the models with and without biomarkers. Results The AUC for invasive breast cancer including only the Gail risk factor variables was 55.3 (95% CI 53.4, 57.1). The AUC increased moderately with the addition of AMH (AUC 57.6, 95% CI 55.7, 59.5), testosterone (AUC 56.2, 95% CI 54.4, 58.1), or both (AUC 58.1, 95% CI 56.2, 59.9). The largest AUC improvement (4.0) was among women without a family history of breast cancer. Conclusions AMH and testosterone moderately increase the discriminatory accuracy of the Gail model among women aged 35–50. We observed the largest AUC increase for women without a family history of breast cancer, the group that would benefit most from improved risk prediction because early screening is already recommended for women with a family history.
topic Breast cancer risk prediction
Anti-Müllerian hormone
Testosterone
Gail model
url http://link.springer.com/article/10.1186/s13058-019-1126-z
work_keys_str_mv AT tessvclendenen breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT wenzhenge breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT karenlkoenig breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT yelenaafanasyeva breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT claudiaagnoli breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT louiseabrinton breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT farboddarvishian breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT joannefdorgan breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT aheathereliassen breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT ronitfalk breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT goranhallmans breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT susanehankinson breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT judithhoffmanbolton breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT timothyjkey breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT vittoriokrogh breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT hazelbnichols breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT dalepsandler breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT minoukjschoemaker breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT patrickmsluss breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT malinsund breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT anthonyjswerdlow breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT kalavisvanathan breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT annezeleniuchjacquotte breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
AT menglingliu breastcancerriskpredictioninwomenaged3550yearsimpactofincludingsexhormoneconcentrationsinthegailmodel
_version_ 1724242440408268800
spelling doaj-5173ace532a544d39c8c04eefe3f07c52021-03-02T05:34:18ZengBMCBreast Cancer Research1465-542X2019-03-0121111210.1186/s13058-019-1126-zBreast cancer risk prediction in women aged 35–50 years: impact of including sex hormone concentrations in the Gail modelTess V. Clendenen0Wenzhen Ge1Karen L. Koenig2Yelena Afanasyeva3Claudia Agnoli4Louise A. Brinton5Farbod Darvishian6Joanne F. Dorgan7A. Heather Eliassen8Roni T. Falk9Göran Hallmans10Susan E. Hankinson11Judith Hoffman-Bolton12Timothy J. Key13Vittorio Krogh14Hazel B. Nichols15Dale P. Sandler16Minouk J. Schoemaker17Patrick M. Sluss18Malin Sund19Anthony J. Swerdlow20Kala Visvanathan21Anne Zeleniuch-Jacquotte22Mengling Liu23Department of Population Health, New York University School of MedicineDepartment of Population Health, New York University School of MedicineDepartment of Population Health, New York University School of MedicineDepartment of Population Health, New York University School of MedicineEpidemiology and Prevention Unit, Fondazione IRCCS - Istituto Nazionale dei TumoriDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of HealthDepartment of Pathology, New York University School of MedicineDepartment of Epidemiology and Public Health, University of Maryland School of MedicineDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, and Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of HealthDepartment of Biobank Research, Public Health and Clinical Medicine, Umeå UniversityDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, and Channing Division of Network Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public HealthCancer Epidemiology Unit, Nuffield Department of Population Health, University of OxfordEpidemiology and Prevention Unit, Fondazione IRCCS - Istituto Nazionale dei TumoriDepartment of Epidemiology, University of North CarolinaEpidemiology Branch, National Institute of Environmental Health SciencesDivision of Genetics and Epidemiology, The Institute of Cancer ResearchDepartment of Pathology, Harvard Medical SchoolDepartment of Surgery, Umeå University HospitalDivision of Genetics and Epidemiology, The Institute of Cancer ResearchDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public HealthDepartment of Population Health, New York University School of MedicineDepartment of Population Health, New York University School of MedicineAbstract Background Models that accurately predict risk of breast cancer are needed to help younger women make decisions about when to begin screening. Premenopausal concentrations of circulating anti-Müllerian hormone (AMH), a biomarker of ovarian reserve, and testosterone have been positively associated with breast cancer risk in prospective studies. We assessed whether adding AMH and/or testosterone to the Gail model improves its prediction performance for women aged 35–50. Methods In a nested case-control study including ten prospective cohorts (1762 invasive cases/1890 matched controls) with pre-diagnostic serum/plasma samples, we estimated relative risks (RR) for the biomarkers and Gail risk factors using conditional logistic regression and random-effects meta-analysis. Absolute risk models were developed using these RR estimates, attributable risk fractions calculated using the distributions of the risk factors in the cases from the consortium, and population-based incidence and mortality rates. The area under the receiver operating characteristic curve (AUC) was used to compare the discriminatory accuracy of the models with and without biomarkers. Results The AUC for invasive breast cancer including only the Gail risk factor variables was 55.3 (95% CI 53.4, 57.1). The AUC increased moderately with the addition of AMH (AUC 57.6, 95% CI 55.7, 59.5), testosterone (AUC 56.2, 95% CI 54.4, 58.1), or both (AUC 58.1, 95% CI 56.2, 59.9). The largest AUC improvement (4.0) was among women without a family history of breast cancer. Conclusions AMH and testosterone moderately increase the discriminatory accuracy of the Gail model among women aged 35–50. We observed the largest AUC increase for women without a family history of breast cancer, the group that would benefit most from improved risk prediction because early screening is already recommended for women with a family history.http://link.springer.com/article/10.1186/s13058-019-1126-zBreast cancer risk predictionAnti-Müllerian hormoneTestosteroneGail model